Brigatinib-associated autoimmune hepatitis: A case report

Buyuksimsek M., Ogul A., Yetisir A. E., Duman B. B., Tohumcuoglu M., Cil T., ...Daha Fazla

Journal of Oncology Pharmacy Practice, cilt.32, sa.4, ss.754-756, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 4
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1177/10781552231171322
  • Dergi Adı: Journal of Oncology Pharmacy Practice
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
  • Sayfa Sayıları: ss.754-756
  • Anahtar Kelimeler: ALK, Autoimmune hepatitis, brigatinib, ROS1
  • Çukurova Üniversitesi Adresli: Evet

Özet

Introduction: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a wide variety of ALK mutations and ROS1 rearrangements. While pancreatic enzyme elevations due to brigatinib are well known, we wanted to present a case that caused liver toxicity. Case report: ALK and ROS1 translocations were detected in a 58-year-old patient diagnosed with metastatic lung adenocarcinoma. In the patient who had a good response with brigatinib, more than 5-fold elevation was detected in liver enzymes at the fifth month of treatment. Management & outcome: After excluding other hepatitis factors, the patient was thought to have autoimmune hepatitis, and methylprednisolone was started and liver enzymes were decreased. Discussion: Increased creatine kinase and lipase levels are common side effects associated with brigatinib, while liver toxicity is rare. Autoimmune hepatitis due to brigatinib was considered because of hepatic toxicity that developed in the fifth month of treatment and responded well to steroids.